Joseph J Palamar1, Alberto Salomone2,3, Rachele Bigiarini3, Marco Vincenti2,3, Patricia Acosta1, Babak Tofighi1,4. 1. a Department of Population Health , New York University Langone Medical Center , New York , NY , USA. 2. b Centro Regionale Antidoping e di Tossicologia "A. Bertinaria" , Orbassano , Turin , Italy. 3. c Dipartimento di Chimica , Università di Torino , Turin , Italy. 4. d Division of General Internal Medicine , New York University School of Medicine , New York , NY , USA.
Abstract
BACKGROUND: Deaths from fentanyl exposure continue to increase in the US. Fentanyl test strips are now available to test urine for presence of fentanyl, but additional testing methods are needed to determine past exposure and to determine exposure to specific analogs. OBJECTIVES: To investigate exposure to such analogs through hair testing. METHODS: Forty individuals in inpatient detoxification (7.5% female) reporting past-month heroin use were surveyed and provided a hair sample to be tested at a later date. While results could not be provided to patients, they were asked how they would respond if informed that their hair tested positive for fentanyl. UHPLC-MS/MS was used to test for past exposure to fentanyl, six other novel synthetic opioids, and fentanyl biomarkers/metabolites. RESULTS: 27.5% reported known fentanyl use in the past year and 67.5% reported suspected exposure. 97.5% (39 of 40) tested positive for fentanyl, 90.0% tested positive for 4-ANPP (a biomarker) and norfentanyl (a metabolite); 82.5% tested positive for acetyl-fentanyl, 47.5% tested positive for furanyl-fentanyl, and 7.5% tested positive for U-47700. Most participants (82.5%) reported they would warn others about fentanyl if they learned their hair tested positive; 75.0% reported they would try to stop using heroin, and 65.0% reported they would ensure that someone nearby has naloxone to reverse a potential overdose. CONCLUSIONS: Hair testing is useful in detecting past exposure to fentanyl, its analogs, and other novel synthetic opioids. Further research is needed to determine whether individuals who use heroin learning about exposure affects drug-taking and treatment-seeking behavior.
BACKGROUND: Deaths from fentanyl exposure continue to increase in the US. Fentanyl test strips are now available to test urine for presence of fentanyl, but additional testing methods are needed to determine past exposure and to determine exposure to specific analogs. OBJECTIVES: To investigate exposure to such analogs through hair testing. METHODS: Forty individuals in inpatient detoxification (7.5% female) reporting past-month heroin use were surveyed and provided a hair sample to be tested at a later date. While results could not be provided to patients, they were asked how they would respond if informed that their hair tested positive for fentanyl. UHPLC-MS/MS was used to test for past exposure to fentanyl, six other novel synthetic opioids, and fentanyl biomarkers/metabolites. RESULTS: 27.5% reported known fentanyl use in the past year and 67.5% reported suspected exposure. 97.5% (39 of 40) tested positive for fentanyl, 90.0% tested positive for 4-ANPP (a biomarker) and norfentanyl (a metabolite); 82.5% tested positive for acetyl-fentanyl, 47.5% tested positive for furanyl-fentanyl, and 7.5% tested positive for U-47700. Most participants (82.5%) reported they would warn others about fentanyl if they learned their hair tested positive; 75.0% reported they would try to stop using heroin, and 65.0% reported they would ensure that someone nearby has naloxone to reverse a potential overdose. CONCLUSIONS: Hair testing is useful in detecting past exposure to fentanyl, its analogs, and other novel synthetic opioids. Further research is needed to determine whether individuals who use heroin learning about exposure affects drug-taking and treatment-seeking behavior.
Entities:
Keywords:
Heroin; adulterants; drug testing; fentanyl; hair testing; harm reduction
Authors: Joseph J Palamar; Alberto Salomone; Enrico Gerace; Daniele Di Corcia; Marco Vincenti; Charles M Cleland Journal: Int J Drug Policy Date: 2017-08-12
Authors: Maxwell S Krieger; Jesse L Yedinak; Jane A Buxton; Mark Lysyshyn; Edward Bernstein; Josiah D Rich; Traci C Green; Scott E Hadland; Brandon D L Marshall Journal: Harm Reduct J Date: 2018-02-08
Authors: Alyona Mazhnaya; Allison O'Rourke; Rebecca Hamilton White; Ju Nyeong Park; Michael E Kilkenny; Susan G Sherman; Sean T Allen Journal: Subst Use Misuse Date: 2020-05-22 Impact factor: 2.164
Authors: A Salomone; R Bigiarini; J J Palamar; C McKnight; L Vinsick; E Amante; D Di Corcia; M Vincenti Journal: J Anal Toxicol Date: 2020-05-18 Impact factor: 3.367
Authors: Logan C Krajewski; Kenneth D Swanson; William A Bragg; Rebecca L Shaner; Craig Seymour; Melissa D Carter; Elizabeth I Hamelin; Rudolph C Johnson Journal: Toxicol Lett Date: 2019-12-05 Impact factor: 4.372
Authors: Andrea Meier; Sarah K Moore; Elizabeth C Saunders; Bethany McLeman; Stephen A Metcalf; Samantha Auty; Olivia Walsh; Lisa A Marsch Journal: Drug Alcohol Depend Date: 2020-02-07 Impact factor: 4.492
Authors: Jan Gryczynski; Helen Nichols; Robert P Schwartz; Shannon Gwin Mitchell; Paulette Hill; Kim Wireman Journal: Drug Alcohol Depend Date: 2019-08-30 Impact factor: 4.492
Authors: Sophia K Chiu; Jennifer L Hornsby-Myers; Marie A de Perio; John E Snawder; Douglas M Wiegand; Douglas Trout; John Howard Journal: Am J Ind Med Date: 2019-04-23 Impact factor: 2.214